logo
Twitter
Discord
Email
logo
Orthofix Medical Inc.

Orthofix Medical Inc.

NASDAQ•OFIX
CEO: Mr. Geoffrey C. Gillespie
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-04-24
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Contact Information
3451 Plano Parkway, Lewisville, TX, 75056, United States
214-937-2000
www.orthofix.com
Market Cap
$556.38M
P/E (TTM)
-4.7
32.4
Dividend Yield
--
52W High
$20.48
52W Low
$10.24
52W Range
37%
Rank38Top 36.9%
4.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$205.63M+4.59%
4-Quarter Trend

EPS

-$0.57-19.72%
4-Quarter Trend

FCF

$2.50M-57.37%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Reported Net Sales Growth Q3 reported net sales totaled $205.6M USD, reflecting 4.6% growth versus prior year period.
Gross Profit Increased 10% Quarterly gross profit reached $148.5M USD, marking a strong 10.0% increase compared to 2024.
EBITDA Margin Expansion Non-GAAP pro forma adjusted EBITDA was $24.6M USD, with margin expanding approximately 233 basis points.
Orthopedics Segment Sales Global Orthopedics segment sales reached $33.6M USD for the quarter, achieving 10.1% reported growth.

Risk Factors

Executive Arbitration Accrual Recorded $18.3M accounting accrual reflecting estimated value of severance/equity rights related to executive arbitration.
M6 Product Line Impairment Recognized $32.2M loss on M6 inventories and long-lived assets impairment during the nine months ended September 30.
SG&A Expense Driven by Legal SG&A increased $18.0M for the quarter, driven primarily by $13.2M associated with ongoing legal matters costs.

Outlook

Debt Covenant Compliance Maintained Confirmed compliance with all required debt-to-EBITDA leverage ratio covenants as of September 30, 2025.
Inventory Efficiency Improved Inventory turns improved to 1.5 times compared to 1.2 times reported in the prior year period.
New Tax Disclosure Adopted Adopted ASU 2023-09 standard for income tax disclosures, effective prospectively starting January 1, 2025.

Peer Comparison

Revenue (TTM)

Varex Imaging CorporationVREX
$844.60M
+4.1%
Orthofix Medical Inc.OFIX
$818.06M
+4.3%
Avanos Medical, Inc.AVNS
$699.90M
+2.7%

Gross Margin (Latest Quarter)

KalVista Pharmaceuticals, Inc.KALV
91.0%
+0.0pp
SI-BONE, Inc.SIBN
79.8%
+0.8pp
Orthofix Medical Inc.OFIX
72.2%
+3.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SVRA$1.18B-10.9-86.6%21.2%
BFLY$1.05B-13.1-37.8%7.3%
KALV$737.98M-3.7-282.0%44.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.6%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 24, 2026
|
EPS:$0.44
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 4, 2025|
    Revenue: $205.63M+4.6%
    |
    EPS: $-0.57-19.7%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $203.12M+2.3%
    |
    EPS: $-0.36-59.1%
    Beat
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 6, 2025|
    Revenue: $193.65M+2.7%
    |
    EPS: $-1.35+42.1%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 25, 2025|
    Revenue: $799.49M+7.1%
    |
    EPS: $-3.30+19.9%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $196.61M+6.8%
    |
    EPS: $-0.71-7.8%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $198.62M+6.2%
    |
    EPS: $-0.88-17.8%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 7, 2024|
    Revenue: $188.61M+7.7%
    |
    EPS: $-0.95-44.4%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 5, 2024|
    Revenue: $746.64M+62.1%
    |
    EPS: $-4.12-320.4%
    Miss